SCI Senior Director, Clinical Operations (Hybrid) Stanford UniversitySCI Senior Director, Clinical Operations (Hybrid)Stanford, CA$195,687–$293,100 / yearThe pay offered to a selected candidate will be determined based on factors such as (but not limited to) the scope and responsibilities of the position, the qualifications of the selected candidate, departmental budget availability, internal equity, geographic location, and external market pay for comparable jobs. Identify, clarify, and resolve issues with strategic impact and substantial significance, which may span multiple areas, using advanced clinical trials operations and Good Clinical Practice (GCP) knowledge requiring broad discretion and judgment.
Sr. Manager / Associate Director, Quality Audits Personalis IncSr. Manager / Associate Director, Quality AuditsFremont, CA$165,000–$210,000 / yearRoot Cause & Investigation Leadership: Provide expert guidance and lead cross-functional investigation teams in executing comprehensive root cause analyses for CAPAs, deviations, and non-conformances stemming from internal and external audits. The successful candidate will have strong leadership skills and possess extensive experience managing Quality Management Systems (QMS) within highly regulated environments, driving compliance, governance, and continuous improvement across the organization with a high degree of autonomy.
Associate Director, Clinical Data Management Revolution Medicines IncAssociate Director, Clinical Data ManagementRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provides CDM oversight of outsourced and partner-resourced clinical trials including scoping trials, project management, relationship management, approval of deliverables, and coordination of internal reviewers.
Senior Director, Clinical Data Management Revolution Medicines IncSenior Director, Clinical Data ManagementRedwood City, CA$244,000–$305,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: The Senior Director of Clinical Data Management provides high-level leadership for data management functions within clinical research, focusing on strategic development, operational execution, and regulatory compliance to ensure data integrity for clinical trials.
Director, Clinical Data Management Revolution Medicines IncDirector, Clinical Data ManagementRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provides CDM oversight of outsourced and partner-resourced clinical trials including scoping trials, project management, relationship management, approval of deliverables, and coordination of internal reviewers.
Associate Director, Clinical Biomarker Development Revolution Medicines IncAssociate Director, Clinical Biomarker DevelopmentRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: The Associate Director in Clinical Biomarker Development team, within Translational Medicine will play a key role in the design, execution, and interpretation of clinical biomarker strategies across Revolution Medicine's oncology pipeline.
Director, Regulatory Affairs Global Filing Lead Revolution Medicines IncDirector, Regulatory Affairs Global Filing LeadRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Required Skills, Experience and Education: Degree in life sciences, pharmacy, medicine, or related fields with a minimum of 12 years in the pharmaceutical/biotech industry or relevant work experience and a minimum of 8 years in Regulatory Affairs including a regulatory strategy role.
Executive Director, Global Patient Safety Quality and Compliance - Pharmacovigilance Revolution Medicines IncExecutive Director, Global Patient Safety Quality and Compliance - PharmacovigilanceRedwood City, CA$265,000–$331,000 / yearThe responsibilities of this role include oversight of the PV-QMS, PV training strategy, PV controlled documentation, inspection and audit management, ensuring inspection readiness, Corrective Action Preventive Action (CAPA) management, Quality Assurance (QA), and maintenance of Good Clinical Practice (GCP), and Good Pharmacovigilance Practices (GVP) in partnership with GPS management, QA, and staff. This critical role will require strategic thinking, expert knowledge of global PV regulations (i.e. GCP, GVP), the ability to influence and communicate ideas effectively, results orientation, collaboration with cross-functional teams, technical expertise, and vendor management skills to ensure compliance with regulatory requirements to safeguard patient well-being.
Director, Global CMC Regulatory Revolution Medicines IncDirector, Global CMC RegulatoryRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Partner with Regulatory Affairs, technical SMEs, and CROs to ensure alignment of global submission strategies while addressing region-specific CMC requirements and serve as the CMC regulatory representative on global commercial teams to provide guidance that enables efficient global execution.
Executive Director, Computational Systems Biology Revolution Medicines IncExecutive Director, Computational Systems BiologyRedwood City, CA$265,000–$331,000 / yearThe individual will lead a team of computational biologists and bioinformaticians focused on acquisition, organization, and analysis of large multi-omics data sets, using both public and proprietary data sources, that will help inform treatment strategies and guide patient stratification for a growing pipeline of RAS(ON) and targeted oncology therapeutics. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Associate Director, Clinical Operations Revolution Medicines IncAssociate Director, Clinical OperationsRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Proven experience working with investigators, external experts and regulatory agencies and oversight of Contract Research Organizations and third-party vendors including realigning with CRO partners when deliverables are at risk, negotiating solutions and leading After Action Reviews to share lessons learned.
Director, Regulatory Affairs - US Filing Lead Revolution Medicines IncDirector, Regulatory Affairs - US Filing LeadRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Required Skills, Experience and Education: Degree in life sciences, pharmacy, medicine, or related fields with a minimum of 12 years in the pharmaceutical/biotech industry or relevant work experience and a minimum of 8 years in Regulatory Affairs including a regulatory strategy role.
Executive Director, Clinical Supply Chain Revolution Medicines IncExecutive Director, Clinical Supply ChainRedwood City, CA$265,000–$331,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Director, US Compliance Revolution Medicines IncDirector, US ComplianceRedwood City, CA$267,000–$306,000 / yearProvide timely, practical, and risk-based compliance advice and counsel on healthcare compliance and policy requirements related to Revolution Medicines interactions with the healthcare community, including disease education programs, promotional and nonpromotional activities, consulting engagements, advisory boards, external funding, patient assistance programs, patient advocacy group interactions, payer interactions, and other similar activities. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Senior Director, Data Science Walmart IncSenior Director, Data ScienceSunnyvale, CA$208,000–$416,000 / yearYour models will serve as the AI engine powering critical consumer facing and enterprise products across Walmart's ecosystem, including Search, Personalization, Sponsored Ads, Conversational Commerce, and Supply Chain Forecasting. The team collaborates closely with stakeholders to drive data strategy, machine learning innovation, and business insights, supporting Walmart's commitment to operational excellence and continuous improvement.
Director of Engineering CollectiveDirector of EngineeringSan Francisco, CaliforniaWe are backed by General Catalyst, Sound Ventures (Ashton Kutcher and Guy Oseary), QED Investors, Google’s Gradient Ventures, Expa, and other investors who have financed iconic companies like YouTube, Substack, Twitch, Box, Hims, Instacart, and Lyft. Our technology and team of trusted advisors help members achieve financial independence by taking care of everything from business incorporation to accounting, bookkeeping, tax services, and access to a thriving community, all in one integrated platform.
Associate Director, Biostatistics Clinical Late Stage Revolution Medicines IncAssociate Director, Biostatistics Clinical Late StageRedwood City, CA$186,000–$233,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Director, US Analytics, Lung Revolution Medicines IncDirector, US Analytics, LungRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. This role will partner closely with Commercial, Medical Affairs, Market Access, Clinical Development, and Business Operations to generate actionable insights that inform portfolio strategy, launch readiness, commercialization planning, and business performance.
Associate Director, Environmental Health and Safety Revolution Medicines IncAssociate Director, Environmental Health and SafetyRedwood City, CA$186,000–$233,000 / yearManage occupational health program activities in partnership with internal stakeholders and external providers, including workplace injury and illness investigation and tracking, animal allergen questionnaire administration and follow-up, hepatitis B vaccination program support, ergonomics program coordination and continuous improvement, and maintenance of related documentation, metrics, and compliance records. Support Facilities Safety Programs through cross-functional collaboration and subject matter expertise, ensuring effective implementation of programs such as electrical safety, lockout/tagout, fall protection, confined space, heat illness prevention, and hot work, while maintaining clear role distinction from program ownership.
Senior Director, Clinical Operations, Global Clinical Vendor Contracts & Budgets Revolution Medicines IncSenior Director, Clinical Operations, Global Clinical Vendor Contracts & BudgetsRedwood City, CA$244,000–$305,000 / yearThe leadership role ensures alignment with strategic objectives, regulatory requirements, and study timelines as well as bringing deep expertise in managing complex trials, contract negotiations, budget development, risk management, and cross-functional collaboration to contribute to the highest quality with on time delivery of RevMed's clinical studies. A member of the Clinical Operations team Leading the Contracts and Outsourcing for all vendor relationships within Clinical Development, the Sr Director Global Vendor Outsourcing will lead the strategic identification and selection process with the teams for vendors and CROs, including scope specifications for clinical programs, and will work closely with the Sr.